ADXS News Alert Advaxis Inc (ADXS) 12.09 01/12/2015 15:50:03
Post# of 64200
Posted On: 01/12/2015 4:49:51 PM
Advaxis Inc (ADXS) 12.09 $ADXS
Advaxis Provides 2014 Year-End Review and 2015 Outlook
GlobeNewswire - Mon Jan 12, 6:30AM CST
Multiple Clinical Milestones Anticipated in 2015 Involving Lm-LLO Cancer Immunotherapy Pipeline
ADXS: 12.09 (+0.79), MRK: 62.30 (-0.26), PETX: 18.67 (+0.07)
Nasdaq stocks posting largest percentage increases
AP - Fri Jan 09, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
HELE: 74.17 (-0.46), AGEN: 6.17 (+0.88), ADXS: 12.09 (+0.79), SCYX: 14.50 (+1.66), ADHD: 5.60 (+0.31), OBAS: 6.31 (-0.90)
Advaxis up as money continues to flow into cancer immunotherapy firms
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 2:47PM CST
ADXS: 12.09 (+0.79)
Advaxis and the GOG Foundation, Inc. to Collaborate on Global Phase 3 Clinical Trial of ADXS-HPV in Cervical Cancer
GlobeNewswire - Wed Jan 07, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it is entering into a clinical trial collaboration agreement with the GOG Foundation, Inc., (GOG Foundation), to evaluate the safety and efficacy of Advaxis's lead cancer immunotherapy, ADXS-HPV, in a global Phase 3 cervical cancer trial. ADXS-HPV is an investigational Lm-LLO immunotherapy bioengineered to generate an immune response to the HPV-associated tumor specific oncogene.
ADXS: 12.09 (+0.79)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 12.09 (+0.79), SGEN: 32.03 (+1.48), GILD: 101.21 (-1.00), OPK: 10.27 (+0.17), MRK: 62.30 (-0.26), IBB: 315.06 (+1.74), AGIO: 131.55 (+3.43), TEVA: 57.01 (+0.29), CELG: 117.00 (+3.33)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 30, 5:31PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 21.45 (+0.25), NEON: 2.87 (-0.02), ADXS: 12.09 (+0.79), QLTI: 4.49 (+0.10), QLT.TO: 5.37 (+0.11), BRID: 7.21 (-0.74), XGTI: 0.50 (+0.10), WVFC: 10.89 (+0.08), BGMD: 0.40 (-0.01), SEED: 1.50 (+0.06), UPI: 1.74 (+0.02), JST: 5.29 (-0.05), GCBC: 29.50 (-0.06), KFFB: 8.10 (+0.08), CJJD: 3.16 (+0.39), MGYR: 8.31 (-0.04)
Equities in the 'Sweet Spot', Spot the Potential: Research Reports on Ambev, Liberty Interactive, Idera, Advaxis, and Juno
PR Newswire - Tue Dec 30, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ambev (NYSE: ABEV), Liberty Interactive (NASDAQ: QVCA), Idera (NASDAQ: IDRA) Advaxis (NASDAQ: ADXS), and Juno (NASDAQ: JUNO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADXS: 12.09 (+0.79), IDRA: 5.37 (+0.40), ABEV: 6.32 (+0.04), JUNO: 61.51 (+7.24), QVCB: 28.42 (+0.11), QVCA: 28.48 (+0.10)
Advaxis's Cancer Immunotherapies Featured on FOX News' Sunday Housecall
GlobeNewswire - Tue Dec 30, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that its Lm-LLO immunotherapy technology was highlighted on FOX News Channel's Sunday Housecall. The segment, which aired on December 28, 2014, featured Drs. Marc Siegel and David Samadi discussing Advaxis's cancer immunotherapy as a potential treatment for a range of cancer indications, including breast, prostate, osteosarcoma, and head and neck, due to its potential to trigger the immune system to directly attack cancer cells.
ADXS: 12.09 (+0.79)
Advaxis (ADXS) Stock Hits New 52-Week High on High Volume
at The Street - Mon Dec 29, 11:32AM CST
Shares of cancer immunotherapy developer Advaxis (ADXS) soared more than 15% to hit a new 52-week high of $9.75 on Monday on higher-than-average volume.
ADXS: 12.09 (+0.79)
Advaxis up again
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 9:16AM CST
ADXS: 12.09 (+0.79)
Advaxis continues cancer immunotherapy-stoked up move
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:58AM CST
ADXS: 12.09 (+0.79), AZN: 70.79 (+1.35)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST
ADXS: 12.09 (+0.79), SANW: 4.28 (+0.27), ASPS: 26.94 (-1.96), OCN: 12.19 (-0.73), ZAZA: 2.43 (-0.20), SGOC: 0.63 (-0.05), AAMC: 321.81 (+9.55), VOC: 5.10 (-0.20), TECU: 3.90 (+0.02), RDUS: 38.90 (-2.02), IRMD: 15.88 (+2.48), SKYS: 10.70 (-0.30), VSCI: 0.63 (+0.03), CALA: 22.86 (-0.78), REXX: 2.94 (-0.74), CFRX: 4.29 (+0.10), TRXC: 3.25 (-0.11), CHNR: 2.06 (-0.05), CNET: 1.35 (-0.07), DRYS: 1.05 (+0.01)
Advaxis Provides 2014 Year-End Review and 2015 Outlook
GlobeNewswire - Mon Jan 12, 6:30AM CST
Multiple Clinical Milestones Anticipated in 2015 Involving Lm-LLO Cancer Immunotherapy Pipeline
ADXS: 12.09 (+0.79), MRK: 62.30 (-0.26), PETX: 18.67 (+0.07)
Nasdaq stocks posting largest percentage increases
AP - Fri Jan 09, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
HELE: 74.17 (-0.46), AGEN: 6.17 (+0.88), ADXS: 12.09 (+0.79), SCYX: 14.50 (+1.66), ADHD: 5.60 (+0.31), OBAS: 6.31 (-0.90)
Advaxis up as money continues to flow into cancer immunotherapy firms
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 2:47PM CST
ADXS: 12.09 (+0.79)
Advaxis and the GOG Foundation, Inc. to Collaborate on Global Phase 3 Clinical Trial of ADXS-HPV in Cervical Cancer
GlobeNewswire - Wed Jan 07, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it is entering into a clinical trial collaboration agreement with the GOG Foundation, Inc., (GOG Foundation), to evaluate the safety and efficacy of Advaxis's lead cancer immunotherapy, ADXS-HPV, in a global Phase 3 cervical cancer trial. ADXS-HPV is an investigational Lm-LLO immunotherapy bioengineered to generate an immune response to the HPV-associated tumor specific oncogene.
ADXS: 12.09 (+0.79)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 12.09 (+0.79), SGEN: 32.03 (+1.48), GILD: 101.21 (-1.00), OPK: 10.27 (+0.17), MRK: 62.30 (-0.26), IBB: 315.06 (+1.74), AGIO: 131.55 (+3.43), TEVA: 57.01 (+0.29), CELG: 117.00 (+3.33)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 30, 5:31PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 21.45 (+0.25), NEON: 2.87 (-0.02), ADXS: 12.09 (+0.79), QLTI: 4.49 (+0.10), QLT.TO: 5.37 (+0.11), BRID: 7.21 (-0.74), XGTI: 0.50 (+0.10), WVFC: 10.89 (+0.08), BGMD: 0.40 (-0.01), SEED: 1.50 (+0.06), UPI: 1.74 (+0.02), JST: 5.29 (-0.05), GCBC: 29.50 (-0.06), KFFB: 8.10 (+0.08), CJJD: 3.16 (+0.39), MGYR: 8.31 (-0.04)
Equities in the 'Sweet Spot', Spot the Potential: Research Reports on Ambev, Liberty Interactive, Idera, Advaxis, and Juno
PR Newswire - Tue Dec 30, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ambev (NYSE: ABEV), Liberty Interactive (NASDAQ: QVCA), Idera (NASDAQ: IDRA) Advaxis (NASDAQ: ADXS), and Juno (NASDAQ: JUNO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADXS: 12.09 (+0.79), IDRA: 5.37 (+0.40), ABEV: 6.32 (+0.04), JUNO: 61.51 (+7.24), QVCB: 28.42 (+0.11), QVCA: 28.48 (+0.10)
Advaxis's Cancer Immunotherapies Featured on FOX News' Sunday Housecall
GlobeNewswire - Tue Dec 30, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that its Lm-LLO immunotherapy technology was highlighted on FOX News Channel's Sunday Housecall. The segment, which aired on December 28, 2014, featured Drs. Marc Siegel and David Samadi discussing Advaxis's cancer immunotherapy as a potential treatment for a range of cancer indications, including breast, prostate, osteosarcoma, and head and neck, due to its potential to trigger the immune system to directly attack cancer cells.
ADXS: 12.09 (+0.79)
Advaxis (ADXS) Stock Hits New 52-Week High on High Volume
at The Street - Mon Dec 29, 11:32AM CST
Shares of cancer immunotherapy developer Advaxis (ADXS) soared more than 15% to hit a new 52-week high of $9.75 on Monday on higher-than-average volume.
ADXS: 12.09 (+0.79)
Advaxis up again
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 9:16AM CST
ADXS: 12.09 (+0.79)
Advaxis continues cancer immunotherapy-stoked up move
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:58AM CST
ADXS: 12.09 (+0.79), AZN: 70.79 (+1.35)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST
ADXS: 12.09 (+0.79), SANW: 4.28 (+0.27), ASPS: 26.94 (-1.96), OCN: 12.19 (-0.73), ZAZA: 2.43 (-0.20), SGOC: 0.63 (-0.05), AAMC: 321.81 (+9.55), VOC: 5.10 (-0.20), TECU: 3.90 (+0.02), RDUS: 38.90 (-2.02), IRMD: 15.88 (+2.48), SKYS: 10.70 (-0.30), VSCI: 0.63 (+0.03), CALA: 22.86 (-0.78), REXX: 2.94 (-0.74), CFRX: 4.29 (+0.10), TRXC: 3.25 (-0.11), CHNR: 2.06 (-0.05), CNET: 1.35 (-0.07), DRYS: 1.05 (+0.01)
(0)
(0)